Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings
Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于2023年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告 | 2025-05-23 | Chinese | |
| 关于作废2023年限制性股票激励计划部分首次授予尚未归属的限制性股票的公告 | 2025-05-15 | Chinese | |
| 第四届监事会第二十一次会议决议公告 | 2025-05-15 | Chinese | |
| 第四届董事会第二十四次会议决议公告 | 2025-05-15 | Chinese | |
| 浙江天册律师事务所关于贝达药业股份有限公司2023年限制性股票激励计划首次授予部分第一个归属期归属条件成就及部分限制性股票作废的法律意见书 | 2025-05-15 | Chinese | |
| 监事会关于2023年限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见 | 2025-05-15 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 37810962 | 关于2023年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告 | 2025-05-23 | Chinese | ||
| 37810943 | 关于作废2023年限制性股票激励计划部分首次授予尚未归属的限制性股票的公告 | 2025-05-15 | Chinese | ||
| 37810928 | 第四届监事会第二十一次会议决议公告 | 2025-05-15 | Chinese | ||
| 37810916 | 第四届董事会第二十四次会议决议公告 | 2025-05-15 | Chinese | ||
| 37810906 | 浙江天册律师事务所关于贝达药业股份有限公司2023年限制性股票激励计划首次授予部分第一个归属期归属条件成就及部分限制性股票作废的法律意见书 | 2025-05-15 | Chinese | ||
| 37810893 | 监事会关于2023年限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见 | 2025-05-15 | Chinese | ||
| 37810882 | 关于2023年限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告 | 2025-05-15 | Chinese | ||
| 37810862 | 董事会薪酬与考核委员会关于2023年限制性股票激励计划相关事项的核查意见 | 2025-05-15 | Chinese | ||
| 37810857 | 关于向澳门药物管理局递交盐酸恩沙替尼胶囊药品上市申请的公告 | 2025-05-12 | Chinese | ||
| 37810839 | 国浩律师（杭州）事务所关于贝达药业股份有限公司2024年年度股东大会的法律意见书 | 2025-05-08 | Chinese | ||
| 37810833 | 2024年度股东大会决议公告 | 2025-05-08 | Chinese | ||
| 37810817 | 中信证券股份有限公司关于贝达药业股份有限公司2024年度募集资金存放与使用情况的核查意见 | 2025-04-29 | Chinese | ||
| 37810803 | 中信证券股份有限公司关于贝达药业股份有限公司使用暂时闲置募集资金进行现金管理的核查意见 | 2025-04-29 | Chinese | ||
| 37810791 | 2025年一季度报告 | 2025-04-24 | Chinese | ||
| 37810787 | 2025年第一季度报告披露提示性公告 | 2025-04-24 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Betta Pharmaceuticals Co.,Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55541/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55541 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55541 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55541 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55541}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Betta Pharmaceuticals Co.,Ltd (id: 55541)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.